Molecular and Clinical Advances in Anticancer Drug Resistance

  • Robert F. Ozols

Part of the Cancer Treatment and Research book series (CTAR, volume 57)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Matilda A. Papathanasiou, Albert J. Fornace Jr.
    Pages 13-36
  3. Marilyn M. Cornwell
    Pages 37-56
  4. Daniel M. Sullivan, Warren E. Ross
    Pages 57-99
  5. Lori J. Goldstein, Michael M. Gottesman, Ira Pastan
    Pages 101-119
  6. William J. Fredericks, YanFeng Chen, Raymond M. Baker
    Pages 121-149
  7. E. G. E. de Vries, H. M. Pinedo
    Pages 171-186
  8. William S. Dalton, Thomas M. Grogan, Thomas P. Miller
    Pages 187-208
  9. Alan Eastman
    Pages 233-249
  10. Robert R. Bahnson, Alakananda Basu, John S. Lazo
    Pages 251-260
  11. Beverly A. Teicher, Emil Frei III
    Pages 261-295
  12. Back Matter
    Pages 297-308

About this book


The importance of drug resistance in cancer chemotherapy cannot be over­ stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors. In the first volume in the series. Drug Resistance in Chemotherapy the results of comprehensive laboratory studies aimed at understanding the mechanisms for resistance to individual agents and to the development of broad cross-resistance were described. In the past 2 years there has been substantial progress in understanding the molecular biology associated with these mechanisms of drug resistance. For the first time we are starting to understand which mechanisms are playing an im­ portant role in human tumors, and even more importantly, clinical trials have recently been initiated in an effort to reverse specific forms of drug resistance. The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance can be circumvented. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e. g. , adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance.


DNA cancer cell chemotherapy clinical trial drug drug resistance molecular biology research resistance

Editors and affiliations

  • Robert F. Ozols
    • 1
  1. 1.Fox Chase Cancer CenterUSA

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic Publishers 1991
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6726-0
  • Online ISBN 978-1-4615-3872-1
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site